# Core Molding Technologies

Type: Company (CMT)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/core-molding-technologies
Canonical HTML page: https://gethealthbrief.com/entity/core-molding-technologies

## Timeline

- **2026-03-10**: FY 2025 Earnings — Legend Biotech reports full-year financial results and 2026 strategic outlook.
- **2025-12-15**: Pipeline Update — Initial Phase 1 data released for solid tumor candidates in neuroendocrine carcinoma.
- **2025-09-30**: Manufacturing Milestone — Ghent facility reaches full operational capacity for commercial production.
- **2025-04-15**: Label Expansion — Carvykti receives FDA approval for earlier lines of multiple myeloma treatment.

## Recent coverage (1 stories)

### Legend Biotech Reports 2025 Results as Carvykti Scales in Early-Line Myeloma
2026-03-10 13:45:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Legend Biotech (LEGN) has released its full-year 2025 financial results, showcasing significant revenue growth driven by the continued commercial expansion of its lead CAR-T therapy, Carvykti. The company highlighted major manufacturing milestones and a strategic pivot toward solid tumor indications following a year of intensive market penetration in earlier lines of multiple myeloma treatment.
Full story: https://gethealthbrief.com/story/legend-biotech-q4-fy2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.